Mind Medicine (MindMed) (MMEDF) Stock Price, News & Analysis

Company Overview

Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.

Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials. The company has established regulatory pathways with health authorities in the United States, Canada and several European countries, positioning itself to generate robust clinical data across multiple therapeutic indications. MindMed has also invested in manufacturing partnerships to support scalable, quality-controlled production of its investigational therapies.

MindMed’s leadership team is led by Chief Executive Officer Rob Barrow, who brings extensive experience in pharmaceutical development and regulatory affairs. Co-founder James Lanthier, who serves as Executive Chair, has guided the company’s strategic vision since inception. The organization has supplemented its in-house expertise with a Scientific Advisory Board composed of psychiatrists, neuroscientists and addiction specialists, ensuring rigorous oversight of study design and clinical protocols.

Through a combination of proprietary drug formulation, clinical collaboration and a commitment to rigorous research, MindMed aims to pioneer a new class of treatment options for mental health and substance-use disorders. The company’s goal is to deliver evidence-based therapies that can transform the standard of care and improve outcomes for patients worldwide.

Key Stats

• Today's Range: $9.38 to $9.67
• 50-Day Range: $7.17 to $10.19
• 52-Week Range: $0.29 to $5.07
• Volume: 761,812 shs
• Average Volume: 3.38 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MMEDF Stock Analysis - Frequently Asked Questions

How have MMEDF shares performed this year?

Mind Medicine (MindMed)'s stock was trading at $6.70 at the start of the year. Since then, MMEDF shares have increased by 42.5% and is now trading at $9.55.

How do I buy shares of Mind Medicine (MindMed)?

Shares of MMEDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MMEDF
• CIK: N/A
• Web: www.mindmed.co
• Phone: (212) 220-6633
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A